{"ticker": {"uuid": "22eec145-0cba-4045-8cae-64f948816d76", "symbol": "ADAG", "name": "Adagene Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Guggenheim reiterates Adagene stock Buy rating on competitor shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQaWt2WFFaMVk5eHpzWHZ6QTE4OFRDWGZhQk8wUFRVaV9kWnQ4aE9JZ3pXZ1Nhc0NpVzJudnB1b2YzZ1BnSEQwVDZ0a0FwVm1oN1dhLV8ySlRmRldfRFd0ck9maDZyVTdFd3dYbDBLNkRaQnhGR0JlSmhyMnRjQ2thWXppcVFKNFBwUWdYRzFtYzFnYmhrQjhOWGlIY0xGNnNiMHB2SXhzNzJzcmY2V1dVRnF4ZGVWSm1KWkNROS1fWDh4MENB?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:49:07+00:00", "published_display": "14 Jul 2026 11:49", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim reiterates Adagene stock Buy rating on competitor shift By Investing.com", "summary": "Guggenheim has reiterated a Buy rating and $10.00 price target for Adagene Inc. (NASDAQ: ADAG) following a competitor's strategic shift in colorectal cancer treatment. The competitor, Agenus Inc., discontinued a Phase 3 study to prioritize development in neoadjuvant colorectal ca", "url": "https://ng.investing.com/news/stock-market-news/guggenheim-reiterates-adagene-stock-buy-rating-on-competitor-shift-93CH-2598622", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T11:11:30", "published_display": "14 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adagene (ADAG) Q4 2025 earnings summary", "summary": "Adagene reported strong clinical progress for Muzastotug in Q4 2025, demonstrating notable response rates and median overall survival in clinical trials for MSS CRC, with favorable safety. The company's cash and cash equivalents stood at $74.5 million, providing a cash runway int", "url": "https://quartr.com/events/adagene-inc-adag-q4-2025_F3S5Bvm6", "source_name": "Quartr", "published_at": "2026-07-09T12:40:44", "published_display": "09 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) H.C. Wainwright 27th Annual Global Investment Conference Summary", "summary": "This article summarizes Adagene's presentation at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting their next-generation antibody therapies for cancer. Key points include their proprietary NEObody, SAFEbody, and POWERbody platforms, strategic collaborati", "url": "https://quartr.com/events/adagene-inc-adag-h-c-wainwright-27th-annual-global-investment-conference_F3S5BEqD", "source_name": "Quartr", "published_at": "2026-07-09T00:41:15", "published_display": "09 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary", "summary": "This article summarizes Adagene's presentation at the Stifel 2026 Targeted Oncology Virtual Forum, highlighting its SAFEbody masking technology for novel masked antibodies like ADG126 (muzastotug). It details ADG126's clinical efficacy and safety profile in combination therapies ", "url": "https://quartr.com/events/adagene-inc-adag-stifel-2026-targeted-oncology-virtual-forum_F3S5yof1", "source_name": "Quartr", "published_at": "2026-07-09T00:38:58", "published_display": "09 Jul 2026 00:38", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article displays financial data for Adagene Inc. under the NASDAQ:ADAG ticker. Specifically, it focuses on the enterprise value to EBITDA forward metric, presenting its period, value, change, and percentage change. The content appears to be a stub or a data point from a fina", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:09:59", "published_display": "07 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K", "summary": "Adagene Inc. (ADAG) reported a preliminary, unaudited cash and cash equivalents balance of US$127.9 million as of June 30, 2026, through a Form 6-K SEC filing. The company emphasized that this figure is subject to finalization and is not a substitute for audited financial stateme", "url": "https://www.stocktitan.net/sec-filings/ADAG/6-k-adagene-inc-current-report-foreign-issuer-cd5e3ed5cc2b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:40:24", "published_display": "06 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article presents the \"Price to book forward\" financial metric for Adagene Inc. (NASDAQ: ADAG). It appears to be a stub or a data-focused page from TradingView, indicating that specific numerical values for the metric were not populated or extracted in this instance. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T10:41:08", "published_display": "06 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Adagene Inc. (NASDAQ: ADAG). It provides a snapshot of this financial ratio for the company, accessible through TradingView's platform. The content is primarily a data label and a navigational entry point r", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T03:39:21", "published_display": "06 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAG - Adagene Inc ADR Website Traffic and Mobile Apps Usage", "summary": "This article provides comprehensive financial data, performance metrics, and news headlines for Adagene Inc. (ADAG). It includes details like market capitalization, P/E ratios, EPS, sales figures, institutional and insider ownership, and recent analyst ratings and company announc", "url": "https://finviz.com/stock?t=ADAG&ty=tr", "source_name": "Finviz", "published_at": "2026-07-05T22:40:24", "published_display": "05 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article provides financial information for Adagene Inc. (NASDAQ: ADAG), specifically focusing on its forward price-to-sales ratio. It presents a quantitative value for this metric along with its percentage change over a specified period. The content appears to be a snapshot ", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T15:40:25", "published_display": "03 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article provides the \"Price to earnings forward\" value for Adagene Inc. (NASDAQ: ADAG). It details the financial metric, along with navigation to other sections like overview, financials, news, and technicals on the TradingView platform for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T22:10:39", "published_display": "02 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Shares Surge 11.43% as Bullish Momentum Builds - SuperTrend", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPd3VFZXBuRTlpYU9BcFZPa2doRXZxaTVBLVAtVWVDQndvN0xkeE1JMzdGVnZSa3UyRTdtWGJpbzI1RndmOXR6NzZ4WmNVeEhIS1pRdG1kaTlybFNFQThCMFpqaTFuRDQycEJ2OV9URGVZUVV6UXl2aWItcl9iT3NBcFBJNHVTdnl0NnlWdUZKUXFhOUY5VXo0VjVsRG9TVVNF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T18:45:43+00:00", "published_display": "01 Jul 2026 18:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG)", "summary": "This article provides an overview of Adagene Inc. (NASDAQ: ADAG) on TradingView, focusing on its financial actuals and estimates. It allows users to explore reported financial data and analyst estimates across income statement, balance sheet, cash flow statement, and valuation me", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:46", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides a forecast and price target for Adagene Inc. (ADAG) on Nasdaq. According to 5 analysts, the 1-year price target for ADAG is 9.40. The page also mentions analyst ratings and details on EPS and Revenue metrics, while disclaiming that the information is not invest", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:42:40", "published_display": "25 Jun 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Q2 2025 Earnings: EPS Misses Estimates, But Stock Surges on Pipeline Progress - Gross Profit Margin", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQd09vdi02bFlLSVlMd09VN3pIcFd4Y0F1Y0FXSlI3bW9seWZhczB0bUpYaEd2dnBnOVJnN216OWY4UlZRYW9tM0R6ZmZyQktjWlBIbU9wQVoyc19EdEVWOURNVlM3OTh1T3lqRnhoXzdCMmMxQUt1Wnl1RVl6RHAxQjFtM0VSLWoySjJwdEN4ck1tVjQ2YlFfM1l5VTh6S3VmQmFhV3g2X3A1MkJGVzBWbHRlV1BQbWkzWmRxSERuNE50ejZHUnNFSzY4YTRSQQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Adagene Inc.'s (ADAG) dividend and stock split history. It states that Adagene Inc. has distributed 0.00 USD in dividends over the past five years and reports \"No Data\" for both dividend payments and stock splits, indicating a lack of such eve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T03:10:57", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (Nasdaq:ADAG) - Stock Analysis", "summary": "Adagene Inc. (NasdaqGM:ADAG) is a clinical-stage biotechnology company focused on monoclonal antibody drugs for cancers. The company's stock is currently trading at US$3.94, with analysts setting a price target of US$9.40. Recent key developments include FDA Fast Track Designatio", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adag/adagene", "source_name": "Simply Wall Street", "published_at": "2026-06-18T03:10:57", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Adagene Inc.'s (ADAG) financial health, focusing on profitability and balance sheet aspects. It reviews key financial indicators like cash and cash equivalents, total assets, total liabilities, free cash flow, total revenue, and operating prof", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:25", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Adagene Inc (ADAG), including current stock data such as market cap and price changes. It lists key institutional shareholders and their shareholdings, highlighting changes for some. The data presented aims to offer", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:28", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Adagene Inc (ADAG), detailing its support, resistance, indicators, and moving averages. According to the analysis, Adagene Inc currently shows more sell signals than buy signals based on its technical indicators and moving averages. T", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/technical", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:28", "published_display": "17 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Adagene Inc (ADAG), including analyst ratings and price targets. Based on 6 analysts, the stock has a \"Buy\" consensus with a target price of USD 11.345, representing a potential upside of 223.22%. The highest forecast is USD 21.07, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:27", "published_display": "17 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc. (ADAG) Q2 2025 Earnings: EPS Misses Estimates as R&D Investments Continue - Quarterly Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbGI4UEVDTGZWX29OU3pzQkRBVEJ5ZzRfbC1IcHZCWnN6WlNqaWVsd3ZDeDAzQ2FYV0hZVjcyNTdlQ2lUdFVjZURjQnVEZFVlTmhSVmIyMmdDaktKZlJDb0dHV1pJOUx1amgxVXdmbnRQOVZaZDdlTDdCRVV0c0FUczMwd1l5cjJYQXFlOFZzYWhKYzBDVVA2THRXUkc3OGtsODQ3eUg2czlMRWRub0pTaFUyUEItUXRsZ1E0dnpJal81Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Upgraded to Buy: Here's What You Should Know", "summary": "Adagene Inc. (ADAG) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive shift in its earnings outlook. This upgrade is driven by an upward trend in earnings estimates, which the Zacks system identifies as a powerful force influencing stock prices. The article sugges", "url": "https://finance.yahoo.com/markets/stocks/articles/adagene-adag-upgraded-buy-heres-160004819.html", "source_name": "Market source", "published_at": "2026-06-05T15:39:14", "published_display": "05 Jun 2026 15:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Adagene (ADAG) This Year?", "summary": "Adagene Inc. Sponsored ADR (ADAG) has significantly outperformed the Medical sector and its specific industry, Medical - Biomedical and Genetics, this year with a 100% year-to-date return. This strong performance is backed by a Zacks Rank of #2 (Buy) and a 37.3% increase in full-", "url": "https://sg.finance.yahoo.com/news/medical-stocks-lagging-adagene-adag-134003612.html", "source_name": "Market source", "published_at": "2026-06-02T13:40:00", "published_display": "02 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer", "summary": "The provided content is merely \"MSN\", which is insufficient to generate a summary. Therefore, no summary can be created based on the given information.", "url": "https://www.msn.com/en-us/health/other/adagene-spotlights-adg126-strategy-as-masked-ctla-4-trial-advances-in-colorectal-cancer/ar-AA23B7JB?uxmode=ruby", "source_name": "MSN", "published_at": "2026-06-01T15:40:53", "published_display": "01 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Q2 2025 Earnings: EPS Misses Estimates; Stock Ticks Up on Pipeline Optimism - Earnings Beat Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcFdPeWJLNVYwcmVDcDA5bkx0RUowbkQ4R2E0OENuaXphNWRQeTJfWE9Sa21YcmdxU3JLMzFsMDZ2TFJmS2FfQUF3R2ZCRVRBdU1aTEgtMzRsVkhhSmtuWHd1MV9BcVE3UXkwdFN1Q09ZTDVhRk0teEw3blNOTmhicXhGei1sS0UtaFptTkRNeVRWX0JQd1pkV3ZyQ0pscEFhVml5MmoyUTAzZk1SQkZVSHdtbjRlSTdtOU9kb1hVZVRRNHI1d184?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Holds Gains Near Resistance After Modest Uptick - Golden Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNY0RSX2ZlMGp0OG82Mnk4Slc2YkE2VnNjVkgyRUlicnd4eWRjb0oyWFR2V3NseFhrY1dzaVZmYUFubFRWSnhDN3lNYXR6ampxck8wMS1mbW93T2hwTHRYVGw3TmQwb1lkbk5fTHcxUjN0ejJuMDBXdWdYeWlKcVF4cWNZOXNoTjZXRE5MZHlIQkVJZUNVOWpzaGFwYUxzMW9nUWVHd0JRUEdmY2s?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc. (ADAG) Q2 2025 Earnings: EPS Misses Estimates Amid R&D Progress - CEO Earnings Statement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWm41b0tVMzVoQWVYa0tqZXQtMEVPRGt2ZzVoa1l4aGJLUUphb3N1NTUxeGxRT3R3Tnc4MHRxWS0wdTNRN2x3ZzJBaDY3YVIyRFoxcGwtRjZwRkg3T0FtRF80WmlLcktxY1RyaG9tdnptbFJUOW1DQUxXY05YWHZobkE5YlJhc0pRMFhINzlIRkxlcFdUOXpiM29hLU1jTldBRGRyREoyaEdUdHRiXzNudjFxUWtQYWdmSUE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc. (ADAG) Q2 2025 Earnings: EPS Misses Estimates Amid R&D Progress - Guidance Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQS1VpZzVuS3k1SGNYWWpqLUkzeXUxeFdZNVBZeXRjMXhIdjNtQVY2cmUtQVdidEZXN0RfbEhPclp2VW9xU2s3MThJUTc5bTA4T2F5WFBBWVU0Z1RfQ0lPMklQTkxOdFJsU19ZUFlPVjRCeHpCWHVtS0NTd01WN1FqMkl5M2JvOGt4bk5VQllQekxOZW8zNVdxM1oxcEVhZnE2cnZVMmVxc0F1TWFUNjJFeDZtRQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement in Thursday's after-market session. It highlights both gainers, such as Akari Therapeutics and BioNTech, and losers, including NervGen Pharma and Adagene, along with their respective percentage changes ", "url": "https://www.benzinga.com/insights/movers/26/05/52734673/12-health-care-stocks-moving-in-thursdays-after-market-session", "source_name": "Benzinga", "published_at": "2026-05-21T21:09:14", "published_display": "21 May 2026 21:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG)", "summary": "WuXi PharmaTech Healthcare Fund I L.P. and its parent, WuXi AppTec Co., Ltd., have reported beneficial ownership of 3,485,038 ordinary shares in Adagene Inc. (NASDAQ: ADAG), equivalent to 2,788,030 American Depositary Shares (ADS), amounting to a 5.9% stake. This information was ", "url": "https://www.stocktitan.net/sec-filings/ADAG/schedule-13g-a-adagene-inc-amended-passive-investment-disclosure-3c48f36d8984.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:10:07", "published_display": "15 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adagene to Participate in Two Upcoming Investor Conferences", "summary": "Adagene Inc. (Nasdaq: ADAG) announced that its senior management will participate in two upcoming investor conferences: the Stifel Annual Virtual Oncology Event on May 19-20, 2026, and the Jefferies LLC Global Healthcare Conference from June 2-4, 2026. The company will hold one-o", "url": "https://www.globenewswire.com/news-release/2026/05/12/3292842/0/en/adagene-to-participate-in-two-upcoming-investor-conferences.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:09:43", "published_display": "12 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adagene-adag-partners-incyte-incy-141533575.html", "source_name": "Insider Monkey", "published_at": "2026-04-20T14:15:33+00:00", "published_display": "20 Apr 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug\u2019s Potential as a Backbone Combination Therapy for Multiple Tumor Types", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adagene-presents-two-posters-aacr-200100813.html", "source_name": "GlobeNewswire", "published_at": "2026-04-17T20:01:00+00:00", "published_display": "17 Apr 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Presents Two Posters at AACR 2026 with New Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxQb0cwUVBrX1dUT29BcGhPNm5NaGx6ZEhIS0ZXRFdYMUJ1dEJaQ1Izak1ZYVI0S2FPcTZxemZkLVpKcHAwbXlvM2dKUkI5Yjhhdlc2MGRMYW9nc0hiWk9IRzJRNzYzUFdlR2dPSkxmR0lmWE02a19GQTBiaTZpRW5id0s1QmNMd0ZwN0lFVjIyb3JvYUtSM2E0WWF3SExNNFd6cTVueGJEVktDZVFtV2dXWUZIeG5odFAyaHBxYzRNZ1JldEFDTFRKN3prUnV5M0cwa1Y0MFIyRkpoUEE2eUg1SDhGTmV4ZGNKUlROdTVNVGV3NXo0LTBJRUZzMUdjb0h1S0NqWDJQc3ozWHpVaGNldU5yX09wUDhDdkFZUjlxd1hxb2VSZXV4QmpObmYyaU80VjhuV19wd091YXZRWW5fZVhSVnY?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWDFiV05CcTZTS0w5Z3pURWxhUkZPaG04a1QyZnJnOVNJRmRORk9GTmYwelM4dFNpeDNieElCRXowWS1SaWtaeDd5Z3VfN3FSNnM3NjkzblBuS282VFhwN1NJYVJnNmVuUWRkQzg1ZnI0VGhJOUtPVGsyaERNOEJUbVVUM0dMSVhQV0t2eG5GQW1XRUI4TUthT3FYaXFiUjQ4Znl6R2VocWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOV1d2Rlo5cFpZZzJNcXRpZXJQMGpPaHliSEZ0b2Y0SF9OQ2l0VWpLaXBDRlMxX3VzUVpqU1dzTklsVTlacGJnVXZjek9EOWZtZ0E0TVg2QUUzZVFSMDZxMXB2VDZlLV9SQ01ZZm83T0N2WjBhdmY1NFRGZFUwSG8tTFNsWUFFMHRxWFNmZERjdDZmcW16RHJvR2UyNU8?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPNXNiNHp5YVVnWHdZVGo1TjJiNFBPRGJnN1JuVWxOT2VENzJWR3d0aXpPLTM2Y0dnZjBSSXNsQ2p6R3dheFBZajQ2SWp4czZqNXdLcEJjR2ZkLXdWNkx5cTFTZTl1VXlMZ2F5ay1ZakVNT0VMYWhVczRqSk0zLUlNZlZRU3pvdTd1MnNZcEliYzJBOW93QlFRTUtCVGMzZ3E2RENlS1BTM2FHMTVaNWxEeGNjR3dwREpqbUtzTzZRb2tRMjR0RzhseUUtbUdldEc1cXhIMGtiOUpBVzlwRk5Gek5DbE8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adagene Inc. Reports Positive Phase 1b/2 Results of ADG126 with Pembrolizumab in Advanced Microsatellite Stable Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxNUDEwdHBuU1hIbGcxNjhWcHZ2R3B3WXY1QlAxNlVlajdfLXhSVEx0RWhwVDdnam90OXQ1RkdqMlVJYkl2cnlSc212X2lnWHhpeHhaTks3V2FxUkp1cUoyRUd2ZGlpdjQ5VEZtRzJ5VThfSTE2bUs3VjMxWmxwbVZQMnpSTXMxYm9OUEVYaDhOTGNKanVhdFRweEhuYlI5MW1HZkZCemdFWWgyOV80SWJ1R2FJRXVJamtxRTlsWUp2N0g1MzZjZ2NFWEpFNmtfSkMtSlhTTVhyTlcxQ1hoaGt5akgwZ0ljMnJINEUzekxmeEJYUGctWXZn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-05-22T07:00:00+00:00", "published_display": "22 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE8wMTFKbWtsdk8wb0Q5WnpVUHAzRlFmQm1yYlJ2QzFRaTVUZUpPUmV3SG5lbzdPeEVkM2UyY3FSSUxUY2EzV2pQYnJmQW1VWVNKSmRz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:35:05+00:00", "published_display": "25 Apr 2025 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Stock Price Forecast. Should You Buy ADAG?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5HSm0tUGJvX291WVotNnlKSVdLVEVpOTJRWmZjbFQ2VVAtUzRia0VPY3BtR2VJMVRydDZNYld1ZzMyMGlUdVRZQg?oc=5", "source_name": "StockInvest.us", "published_at": "2021-02-16T07:29:34+00:00", "published_display": "16 Feb 2021 07:29", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Adagene (ADAG)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE84V29od0N4bUNRWVdQbEFQVkF2MVhkOTM2RUNsTWV4RjZ0aXV4TjFRdDJUZ2VmWkRkUXVNVjk3UENlYkl6NTBINFAxNkR4MVAyZWlqSXNwLTV2Y0xxV3oySHYtN2pPUTB0QW5hcA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-02-13T07:14:35+00:00", "published_display": "13 Feb 2021 07:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Guggenheim reiterates Adagene stock Buy rating on competitor shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQaWt2WFFaMVk5eHpzWHZ6QTE4OFRDWGZhQk8wUFRVaV9kWnQ4aE9JZ3pXZ1Nhc0NpVzJudnB1b2YzZ1BnSEQwVDZ0a0FwVm1oN1dhLV8ySlRmRldfRFd0ck9maDZyVTdFd3dYbDBLNkRaQnhGR0JlSmhyMnRjQ2thWXppcVFKNFBwUWdYRzFtYzFnYmhrQjhOWGlIY0xGNnNiMHB2SXhzNzJzcmY2V1dVRnF4ZGVWSm1KWkNROS1fWDh4MENB?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:49:07+00:00", "published_display": "14 Jul 2026 11:49", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim reiterates Adagene stock Buy rating on competitor shift By Investing.com", "summary": "Guggenheim has reiterated a Buy rating and $10.00 price target for Adagene Inc. (NASDAQ: ADAG) following a competitor's strategic shift in colorectal cancer treatment. The competitor, Agenus Inc., discontinued a Phase 3 study to prioritize development in neoadjuvant colorectal ca", "url": "https://ng.investing.com/news/stock-market-news/guggenheim-reiterates-adagene-stock-buy-rating-on-competitor-shift-93CH-2598622", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T11:11:30", "published_display": "14 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Q4 2025 earnings summary", "summary": "Adagene reported strong clinical progress for Muzastotug in Q4 2025, demonstrating notable response rates and median overall survival in clinical trials for MSS CRC, with favorable safety. The company's cash and cash equivalents stood at $74.5 million, providing a cash runway int", "url": "https://quartr.com/events/adagene-inc-adag-q4-2025_F3S5Bvm6", "source_name": "Quartr", "published_at": "2026-07-09T12:40:44", "published_display": "09 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) H.C. Wainwright 27th Annual Global Investment Conference Summary", "summary": "This article summarizes Adagene's presentation at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting their next-generation antibody therapies for cancer. Key points include their proprietary NEObody, SAFEbody, and POWERbody platforms, strategic collaborati", "url": "https://quartr.com/events/adagene-inc-adag-h-c-wainwright-27th-annual-global-investment-conference_F3S5BEqD", "source_name": "Quartr", "published_at": "2026-07-09T00:41:15", "published_display": "09 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary", "summary": "This article summarizes Adagene's presentation at the Stifel 2026 Targeted Oncology Virtual Forum, highlighting its SAFEbody masking technology for novel masked antibodies like ADG126 (muzastotug). It details ADG126's clinical efficacy and safety profile in combination therapies ", "url": "https://quartr.com/events/adagene-inc-adag-stifel-2026-targeted-oncology-virtual-forum_F3S5yof1", "source_name": "Quartr", "published_at": "2026-07-09T00:38:58", "published_display": "09 Jul 2026 00:38", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article displays financial data for Adagene Inc. under the NASDAQ:ADAG ticker. Specifically, it focuses on the enterprise value to EBITDA forward metric, presenting its period, value, change, and percentage change. The content appears to be a stub or a data point from a fina", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:09:59", "published_display": "07 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K", "summary": "Adagene Inc. (ADAG) reported a preliminary, unaudited cash and cash equivalents balance of US$127.9 million as of June 30, 2026, through a Form 6-K SEC filing. The company emphasized that this figure is subject to finalization and is not a substitute for audited financial stateme", "url": "https://www.stocktitan.net/sec-filings/ADAG/6-k-adagene-inc-current-report-foreign-issuer-cd5e3ed5cc2b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:40:24", "published_display": "06 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article presents the \"Price to book forward\" financial metric for Adagene Inc. (NASDAQ: ADAG). It appears to be a stub or a data-focused page from TradingView, indicating that specific numerical values for the metric were not populated or extracted in this instance. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T10:41:08", "published_display": "06 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Adagene Inc. (NASDAQ: ADAG). It provides a snapshot of this financial ratio for the company, accessible through TradingView's platform. The content is primarily a data label and a navigational entry point r", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T03:39:21", "published_display": "06 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAG - Adagene Inc ADR Website Traffic and Mobile Apps Usage", "summary": "This article provides comprehensive financial data, performance metrics, and news headlines for Adagene Inc. (ADAG). It includes details like market capitalization, P/E ratios, EPS, sales figures, institutional and insider ownership, and recent analyst ratings and company announc", "url": "https://finviz.com/stock?t=ADAG&ty=tr", "source_name": "Finviz", "published_at": "2026-07-05T22:40:24", "published_display": "05 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article provides financial information for Adagene Inc. (NASDAQ: ADAG), specifically focusing on its forward price-to-sales ratio. It presents a quantitative value for this metric along with its percentage change over a specified period. The content appears to be a snapshot ", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T15:40:25", "published_display": "03 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Adagene Inc. \u2013 NASDAQ:ADAG", "summary": "This article provides the \"Price to earnings forward\" value for Adagene Inc. (NASDAQ: ADAG). It details the financial metric, along with navigation to other sections like overview, financials, news, and technicals on the TradingView platform for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T22:10:39", "published_display": "02 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Shares Surge 11.43% as Bullish Momentum Builds - SuperTrend", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPd3VFZXBuRTlpYU9BcFZPa2doRXZxaTVBLVAtVWVDQndvN0xkeE1JMzdGVnZSa3UyRTdtWGJpbzI1RndmOXR6NzZ4WmNVeEhIS1pRdG1kaTlybFNFQThCMFpqaTFuRDQycEJ2OV9URGVZUVV6UXl2aWItcl9iT3NBcFBJNHVTdnl0NnlWdUZKUXFhOUY5VXo0VjVsRG9TVVNF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T18:45:43+00:00", "published_display": "01 Jul 2026 18:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG)", "summary": "This article provides an overview of Adagene Inc. (NASDAQ: ADAG) on TradingView, focusing on its financial actuals and estimates. It allows users to explore reported financial data and analyst estimates across income statement, balance sheet, cash flow statement, and valuation me", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:46", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides a forecast and price target for Adagene Inc. (ADAG) on Nasdaq. According to 5 analysts, the 1-year price target for ADAG is 9.40. The page also mentions analyst ratings and details on EPS and Revenue metrics, while disclaiming that the information is not invest", "url": "https://www.tradingview.com/symbols/NASDAQ-ADAG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:42:40", "published_display": "25 Jun 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Q2 2025 Earnings: EPS Misses Estimates, But Stock Surges on Pipeline Progress - Gross Profit Margin", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQd09vdi02bFlLSVlMd09VN3pIcFd4Y0F1Y0FXSlI3bW9seWZhczB0bUpYaEd2dnBnOVJnN216OWY4UlZRYW9tM0R6ZmZyQktjWlBIbU9wQVoyc19EdEVWOURNVlM3OTh1T3lqRnhoXzdCMmMxQUt1Wnl1RVl6RHAxQjFtM0VSLWoySjJwdEN4ck1tVjQ2YlFfM1l5VTh6S3VmQmFhV3g2X3A1MkJGVzBWbHRlV1BQbWkzWmRxSERuNE50ejZHUnNFSzY4YTRSQQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Adagene Inc.'s (ADAG) dividend and stock split history. It states that Adagene Inc. has distributed 0.00 USD in dividends over the past five years and reports \"No Data\" for both dividend payments and stock splits, indicating a lack of such eve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T03:10:57", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (Nasdaq:ADAG) - Stock Analysis", "summary": "Adagene Inc. (NasdaqGM:ADAG) is a clinical-stage biotechnology company focused on monoclonal antibody drugs for cancers. The company's stock is currently trading at US$3.94, with analysts setting a price target of US$9.40. Recent key developments include FDA Fast Track Designatio", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adag/adagene", "source_name": "Simply Wall Street", "published_at": "2026-06-18T03:10:57", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Adagene Inc.'s (ADAG) financial health, focusing on profitability and balance sheet aspects. It reviews key financial indicators like cash and cash equivalents, total assets, total liabilities, free cash flow, total revenue, and operating prof", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:25", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Adagene Inc (ADAG), including current stock data such as market cap and price changes. It lists key institutional shareholders and their shareholdings, highlighting changes for some. The data presented aims to offer", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:28", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Adagene Inc (ADAG), detailing its support, resistance, indicators, and moving averages. According to the analysis, Adagene Inc currently shows more sell signals than buy signals based on its technical indicators and moving averages. T", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/technical", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:28", "published_display": "17 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc (ADAG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Adagene Inc (ADAG), including analyst ratings and price targets. Based on 6 analysts, the stock has a \"Buy\" consensus with a target price of USD 11.345, representing a potential upside of 223.22%. The highest forecast is USD 21.07, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adag/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:27", "published_display": "17 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc. (ADAG) Q2 2025 Earnings: EPS Misses Estimates as R&D Investments Continue - Quarterly Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbGI4UEVDTGZWX29OU3pzQkRBVEJ5ZzRfbC1IcHZCWnN6WlNqaWVsd3ZDeDAzQ2FYV0hZVjcyNTdlQ2lUdFVjZURjQnVEZFVlTmhSVmIyMmdDaktKZlJDb0dHV1pJOUx1amgxVXdmbnRQOVZaZDdlTDdCRVV0c0FUczMwd1l5cjJYQXFlOFZzYWhKYzBDVVA2THRXUkc3OGtsODQ3eUg2czlMRWRub0pTaFUyUEItUXRsZ1E0dnpJal81Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Upgraded to Buy: Here's What You Should Know", "summary": "Adagene Inc. (ADAG) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive shift in its earnings outlook. This upgrade is driven by an upward trend in earnings estimates, which the Zacks system identifies as a powerful force influencing stock prices. The article sugges", "url": "https://finance.yahoo.com/markets/stocks/articles/adagene-adag-upgraded-buy-heres-160004819.html", "source_name": "Market source", "published_at": "2026-06-05T15:39:14", "published_display": "05 Jun 2026 15:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Adagene (ADAG) This Year?", "summary": "Adagene Inc. Sponsored ADR (ADAG) has significantly outperformed the Medical sector and its specific industry, Medical - Biomedical and Genetics, this year with a 100% year-to-date return. This strong performance is backed by a Zacks Rank of #2 (Buy) and a 37.3% increase in full-", "url": "https://sg.finance.yahoo.com/news/medical-stocks-lagging-adagene-adag-134003612.html", "source_name": "Market source", "published_at": "2026-06-02T13:40:00", "published_display": "02 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer", "summary": "The provided content is merely \"MSN\", which is insufficient to generate a summary. Therefore, no summary can be created based on the given information.", "url": "https://www.msn.com/en-us/health/other/adagene-spotlights-adg126-strategy-as-masked-ctla-4-trial-advances-in-colorectal-cancer/ar-AA23B7JB?uxmode=ruby", "source_name": "MSN", "published_at": "2026-06-01T15:40:53", "published_display": "01 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Q2 2025 Earnings: EPS Misses Estimates; Stock Ticks Up on Pipeline Optimism - Earnings Beat Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcFdPeWJLNVYwcmVDcDA5bkx0RUowbkQ4R2E0OENuaXphNWRQeTJfWE9Sa21YcmdxU3JLMzFsMDZ2TFJmS2FfQUF3R2ZCRVRBdU1aTEgtMzRsVkhhSmtuWHd1MV9BcVE3UXkwdFN1Q09ZTDVhRk0teEw3blNOTmhicXhGei1sS0UtaFptTkRNeVRWX0JQd1pkV3ZyQ0pscEFhVml5MmoyUTAzZk1SQkZVSHdtbjRlSTdtOU9kb1hVZVRRNHI1d184?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Holds Gains Near Resistance After Modest Uptick - Golden Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNY0RSX2ZlMGp0OG82Mnk4Slc2YkE2VnNjVkgyRUlicnd4eWRjb0oyWFR2V3NseFhrY1dzaVZmYUFubFRWSnhDN3lNYXR6ampxck8wMS1mbW93T2hwTHRYVGw3TmQwb1lkbk5fTHcxUjN0ejJuMDBXdWdYeWlKcVF4cWNZOXNoTjZXRE5MZHlIQkVJZUNVOWpzaGFwYUxzMW9nUWVHd0JRUEdmY2s?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc. (ADAG) Q2 2025 Earnings: EPS Misses Estimates Amid R&D Progress - CEO Earnings Statement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWm41b0tVMzVoQWVYa0tqZXQtMEVPRGt2ZzVoa1l4aGJLUUphb3N1NTUxeGxRT3R3Tnc4MHRxWS0wdTNRN2x3ZzJBaDY3YVIyRFoxcGwtRjZwRkg3T0FtRF80WmlLcktxY1RyaG9tdnptbFJUOW1DQUxXY05YWHZobkE5YlJhc0pRMFhINzlIRkxlcFdUOXpiM29hLU1jTldBRGRyREoyaEdUdHRiXzNudjFxUWtQYWdmSUE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc. (ADAG) Q2 2025 Earnings: EPS Misses Estimates Amid R&D Progress - Guidance Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQS1VpZzVuS3k1SGNYWWpqLUkzeXUxeFdZNVBZeXRjMXhIdjNtQVY2cmUtQVdidEZXN0RfbEhPclp2VW9xU2s3MThJUTc5bTA4T2F5WFBBWVU0Z1RfQ0lPMklQTkxOdFJsU19ZUFlPVjRCeHpCWHVtS0NTd01WN1FqMkl5M2JvOGt4bk5VQllQekxOZW8zNVdxM1oxcEVhZnE2cnZVMmVxc0F1TWFUNjJFeDZtRQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement in Thursday's after-market session. It highlights both gainers, such as Akari Therapeutics and BioNTech, and losers, including NervGen Pharma and Adagene, along with their respective percentage changes ", "url": "https://www.benzinga.com/insights/movers/26/05/52734673/12-health-care-stocks-moving-in-thursdays-after-market-session", "source_name": "Benzinga", "published_at": "2026-05-21T21:09:14", "published_display": "21 May 2026 21:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG)", "summary": "WuXi PharmaTech Healthcare Fund I L.P. and its parent, WuXi AppTec Co., Ltd., have reported beneficial ownership of 3,485,038 ordinary shares in Adagene Inc. (NASDAQ: ADAG), equivalent to 2,788,030 American Depositary Shares (ADS), amounting to a 5.9% stake. This information was ", "url": "https://www.stocktitan.net/sec-filings/ADAG/schedule-13g-a-adagene-inc-amended-passive-investment-disclosure-3c48f36d8984.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:10:07", "published_display": "15 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene to Participate in Two Upcoming Investor Conferences", "summary": "Adagene Inc. (Nasdaq: ADAG) announced that its senior management will participate in two upcoming investor conferences: the Stifel Annual Virtual Oncology Event on May 19-20, 2026, and the Jefferies LLC Global Healthcare Conference from June 2-4, 2026. The company will hold one-o", "url": "https://www.globenewswire.com/news-release/2026/05/12/3292842/0/en/adagene-to-participate-in-two-upcoming-investor-conferences.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:09:43", "published_display": "12 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adagene-adag-partners-incyte-incy-141533575.html", "source_name": "Insider Monkey", "published_at": "2026-04-20T14:15:33+00:00", "published_display": "20 Apr 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug\u2019s Potential as a Backbone Combination Therapy for Multiple Tumor Types", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adagene-presents-two-posters-aacr-200100813.html", "source_name": "GlobeNewswire", "published_at": "2026-04-17T20:01:00+00:00", "published_display": "17 Apr 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Presents Two Posters at AACR 2026 with New Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxQb0cwUVBrX1dUT29BcGhPNm5NaGx6ZEhIS0ZXRFdYMUJ1dEJaQ1Izak1ZYVI0S2FPcTZxemZkLVpKcHAwbXlvM2dKUkI5Yjhhdlc2MGRMYW9nc0hiWk9IRzJRNzYzUFdlR2dPSkxmR0lmWE02a19GQTBiaTZpRW5id0s1QmNMd0ZwN0lFVjIyb3JvYUtSM2E0WWF3SExNNFd6cTVueGJEVktDZVFtV2dXWUZIeG5odFAyaHBxYzRNZ1JldEFDTFRKN3prUnV5M0cwa1Y0MFIyRkpoUEE2eUg1SDhGTmV4ZGNKUlROdTVNVGV3NXo0LTBJRUZzMUdjb0h1S0NqWDJQc3ozWHpVaGNldU5yX09wUDhDdkFZUjlxd1hxb2VSZXV4QmpObmYyaU80VjhuV19wd091YXZRWW5fZVhSVnY?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWDFiV05CcTZTS0w5Z3pURWxhUkZPaG04a1QyZnJnOVNJRmRORk9GTmYwelM4dFNpeDNieElCRXowWS1SaWtaeDd5Z3VfN3FSNnM3NjkzblBuS282VFhwN1NJYVJnNmVuUWRkQzg1ZnI0VGhJOUtPVGsyaERNOEJUbVVUM0dMSVhQV0t2eG5GQW1XRUI4TUthT3FYaXFiUjQ4Znl6R2VocWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOV1d2Rlo5cFpZZzJNcXRpZXJQMGpPaHliSEZ0b2Y0SF9OQ2l0VWpLaXBDRlMxX3VzUVpqU1dzTklsVTlacGJnVXZjek9EOWZtZ0E0TVg2QUUzZVFSMDZxMXB2VDZlLV9SQ01ZZm83T0N2WjBhdmY1NFRGZFUwSG8tTFNsWUFFMHRxWFNmZERjdDZmcW16RHJvR2UyNU8?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPNXNiNHp5YVVnWHdZVGo1TjJiNFBPRGJnN1JuVWxOT2VENzJWR3d0aXpPLTM2Y0dnZjBSSXNsQ2p6R3dheFBZajQ2SWp4czZqNXdLcEJjR2ZkLXdWNkx5cTFTZTl1VXlMZ2F5ay1ZakVNT0VMYWhVczRqSk0zLUlNZlZRU3pvdTd1MnNZcEliYzJBOW93QlFRTUtCVGMzZ3E2RENlS1BTM2FHMTVaNWxEeGNjR3dwREpqbUtzTzZRb2tRMjR0RzhseUUtbUdldEc1cXhIMGtiOUpBVzlwRk5Gek5DbE8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Inc. Reports Positive Phase 1b/2 Results of ADG126 with Pembrolizumab in Advanced Microsatellite Stable Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxNUDEwdHBuU1hIbGcxNjhWcHZ2R3B3WXY1QlAxNlVlajdfLXhSVEx0RWhwVDdnam90OXQ1RkdqMlVJYkl2cnlSc212X2lnWHhpeHhaTks3V2FxUkp1cUoyRUd2ZGlpdjQ5VEZtRzJ5VThfSTE2bUs3VjMxWmxwbVZQMnpSTXMxYm9OUEVYaDhOTGNKanVhdFRweEhuYlI5MW1HZkZCemdFWWgyOV80SWJ1R2FJRXVJamtxRTlsWUp2N0g1MzZjZ2NFWEpFNmtfSkMtSlhTTVhyTlcxQ1hoaGt5akgwZ0ljMnJINEUzekxmeEJYUGctWXZn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-05-22T07:00:00+00:00", "published_display": "22 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene (ADAG) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE8wMTFKbWtsdk8wb0Q5WnpVUHAzRlFmQm1yYlJ2QzFRaTVUZUpPUmV3SG5lbzdPeEVkM2UyY3FSSUxUY2EzV2pQYnJmQW1VWVNKSmRz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:35:05+00:00", "published_display": "25 Apr 2025 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adagene Stock Price Forecast. Should You Buy ADAG?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5HSm0tUGJvX291WVotNnlKSVdLVEVpOTJRWmZjbFQ2VVAtUzRia0VPY3BtR2VJMVRydDZNYld1ZzMyMGlUdVRZQg?oc=5", "source_name": "StockInvest.us", "published_at": "2021-02-16T07:29:34+00:00", "published_display": "16 Feb 2021 07:29", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Adagene (ADAG)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE84V29od0N4bUNRWVdQbEFQVkF2MVhkOTM2RUNsTWV4RjZ0aXV4TjFRdDJUZ2VmWkRkUXVNVjk3UENlYkl6NTBINFAxNkR4MVAyZWlqSXNwLTV2Y0xxV3oySHYtN2pPUTB0QW5hcA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-02-13T07:14:35+00:00", "published_display": "13 Feb 2021 07:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 51, "sentiment_summary": {"positive": 13, "negative": 10, "neutral": 28, "score": 52, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 12.25, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 10.45, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 3.94, "latest_week": "2026-07-10", "one_week_move": -11.9, "four_week_move": 10.4, "twelve_week_move": -0.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.022922, "market_dynamics_buy_signal": false, "relative_strength": 26.516149, "fair_value_gap": 68.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.3963, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-11.9% over one week, +10.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 5}, {"label": "dars.gov.et", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "Donan\u0131mHaber", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 21}, {"label": "Market update", "count": 21}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-11.9% over one week, +10.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Guggenheim reiterates Adagene stock Buy rating on competitor shift"}], "updated_at": "2026-07-16T15:24:37.808665+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}